These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 21249321)

  • 21. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
    Weigel MT; Meinhold-Heerlein I; Bauerschlag DO; Schem C; Bauer M; Jonat W; Maass N; Mundhenke C
    Cancer Lett; 2009 Jan; 273(1):70-9. PubMed ID: 18809244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
    Krug LM; Crapanzano JP; Azzoli CG; Miller VA; Rizvi N; Gomez J; Kris MG; Pizzo B; Tyson L; Dunne M; Heelan RT
    Cancer; 2005 May; 103(10):2128-31. PubMed ID: 15812822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of imatinib mesylate (Glivec) on human tumor-derived cells.
    Knight LA; Di Nicolantonio F; Whitehouse PA; Mercer SJ; Sharma S; Glaysher S; Hungerford JL; Hurren J; Lamont A; Cree IA
    Anticancer Drugs; 2006 Jul; 17(6):649-55. PubMed ID: 16917210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of MMP-2, -9 and -13 in cell lines and fresh biopsies of squamous cell carcinomas of the upper aerodigestive tract.
    Dünne AA; Sesterhenn A; Gerisch A; Teymoortash A; Kuropkat C; Werner JA
    Anticancer Res; 2003; 23(3B):2233-9. PubMed ID: 12894497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic effects of imatinib (STI 571) in combination with chemotherapeutic drugs in head and neck cancer.
    Bruce IA; Slevin NJ; Homer JJ; McGown AT; Ward TH
    Anticancer Drugs; 2005 Aug; 16(7):719-26. PubMed ID: 16027519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation.
    Cilloni D; Messa F; Gottardi E; Fava M; Arruga F; Defilippi I; Carturan S; Messa E; Morotti A; Giugliano E; Rege-Cambrin G; Alberti D; Baccarani M; Saglio G
    Cancer; 2004 Sep; 101(5):979-88. PubMed ID: 15329907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of Smad signaling enhances collagenase-3 (MMP-13) expression and invasion of head and neck squamous carcinoma cells.
    Leivonen SK; Ala-Aho R; Koli K; Grénman R; Peltonen J; Kähäri VM
    Oncogene; 2006 Apr; 25(18):2588-600. PubMed ID: 16407850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
    Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Kobayashi T; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Emi N; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
    J Clin Oncol; 2006 Jan; 24(3):460-6. PubMed ID: 16344315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sulindac sulfone induces a decrease of beta-catenin in HNSCC.
    Sauter A; Soulsby H; Hormann K; Naim R
    Anticancer Res; 2010 Feb; 30(2):339-43. PubMed ID: 20332437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New oncological treatment principle with imatinib].
    Kuenen BC; Pinedo HM
    Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2044-5. PubMed ID: 14606348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.
    Rodriguez-Pinilla M; Rodriguez-Peralto JL; Hitt R; Sanchez JJ; Ballestin C; Diez A; Sanchez-Verde L; Alameda F; Sanchez-Cespedes M
    Clin Cancer Res; 2004 Dec; 10(24):8486-92. PubMed ID: 15623629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
    Usui N
    Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p38alpha and p38delta mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells.
    Junttila MR; Ala-Aho R; Jokilehto T; Peltonen J; Kallajoki M; Grenman R; Jaakkola P; Westermarck J; Kähäri VM
    Oncogene; 2007 Aug; 26(36):5267-79. PubMed ID: 17334397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).
    Hotfilder M; Lanvers C; Jürgens H; Boos J; Vormoor J
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):167-9. PubMed ID: 12172985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
    Deininger MW; Vieira SA; Parada Y; Banerji L; Lam EW; Peters G; Mahon FX; Köhler T; Goldman JM; Melo JV
    Cancer Res; 2001 Nov; 61(21):8005-13. PubMed ID: 11691826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Matrix metalloproteinase-2 and -14 in p16-positive and -negative HNSCC after exposure To 5-FU and docetaxel In Vitro.
    Aderhold C; Umbreit C; Faber A; Birk R; Sommer JU; Hörmann K; Schultz JD
    Anticancer Res; 2014 Sep; 34(9):4929-37. PubMed ID: 25202075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects.
    Mundhenke C; Weigel MT; Sturner KH; Roesel F; Meinhold-Heerlein I; Bauerschlag DO; Schem C; Hilpert F; Jonat W; Maass N
    J Cancer Res Clin Oncol; 2008 Dec; 134(12):1397-405. PubMed ID: 18465140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined effects of lapatinib and cisplatin on colony formation of head and neck squamous cell carcinoma.
    Schrader C; Boehm A; Reiche A; Dietz A; Mozet C; Wichmann G
    Anticancer Res; 2012 Aug; 32(8):3191-9. PubMed ID: 22843892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A synthetic matrix metalloproteinase inhibitor prevents squamous carcinoma cell proliferation by interfering with epidermal growth factor receptor autocrine loops.
    O-Charoenrat P; Rhys-Evans P; Eccles S
    Int J Cancer; 2002 Aug; 100(5):527-33. PubMed ID: 12124801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic role of MMP-9 expression in head and neck carcinoma patients treated with radiotherapy or chemoradiotherapy.
    Virós D; Camacho M; Zarraonandia I; García J; Quer M; Vila L; León X
    Oral Oncol; 2013 Apr; 49(4):322-5. PubMed ID: 23122824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.